Britain’s health technology assessor (HTA) is moving to recommend against funding Casgevy (exagamglogene autotemcel), the second such blow for people with sickl 15 March 2024
Early data from the AFFINITY DUCHENNE trial of a new gene therapy, RGX-202, raise hopes for a breakthrough in Duchenne muscular dystrophy (DMD). 6 March 2024
Progress is happening in the cell and gene therapies (CGT) space—but that does not mean that the challenges that have held it back are about to disappear. 6 March 2024
There is a ray of hope for sickle cell disease (SCD) patients in the UK, after the British health technology assessor re-opened its review into Oxbryta (voxelot 1 March 2024
British pharma major AstraZeneca has chosen Shanghai as the location for what will become its fifth global strategic center for research and development. 29 February 2024
San Diego-based Kenai Therapeutics, a biotech leveraging induced pluripotent stem cell (iPSC) tech to discover and develop a platform of allogeneic neuron repla 29 February 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.